| 1 |
Woolhouse I, Bishop L, Darlison L, et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma[J]. Thorax, 2018, 73(Suppl 1): i1-i30.
|
| 2 |
Süß C, Kölbl O. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline[J]. Strahlenther Onkol, 2018, 194(10): 953-957.
|
| 3 |
Tanrikulu AC, Abakay A, Kaplan MA, et al. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma[J]. Respiration, 2010, 80(6): 480-487.
|
| 4 |
王 帅，马 可，詹 成，等. 恶性胸膜间皮瘤(MPM)分期的研究进展[J]. 复旦学报(医学版), 2019, 46(01): 108-113.
|
| 5 |
Seely JM, Nguyen ET, Churg AM, et al. Malignant pleural mesothelioma：computed tomography and correlation with histology[J]. Eur J Radiol, 2009, 70(3): 485-491.
|
| 6 |
Hallifax RJ, Haris M, Corcoran JP, et al. Role of CT in assessing pleural malignancy prior to thoracoscopy[J]. Thorax, 2015, 70(2): 192-193.
|
| 7 |
Hierholzer J, Luo L, Bittner RC, et al. MRI and CT in the differential diagnosis of pleural disease[J]. Chest, 2000, 118(3): 604-609.
|
| 8 |
Elboga U, Ylmaz M, Uyar M, et al. The role of FDG PET-CT in differential diagnosis of pleural pathologies[J]. Rev Esp Med Nucl Imagen Mol, 2012, 31(4): 187-191.
|
| 9 |
Rahman NM, Ali NJ, Brown G, et al. Local anaesthetic thoracoscopy：British Thoracic Society Pleural Disease Guideline 2010[J]. Thorax, 2010, 65 Suppl 2: ii54-60.
|
| 10 |
Wu D, Hiroshima K, Matsumoto S, et al. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis[J]. Am J Clin Pathol, 2013, 139(1): 39-46.
|
| 11 |
Filiberti R, Marroni P, Spigno F, et al. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos[J]. Oncology, 2014, 86(1): 33-43.
|
| 12 |
Hollevoet K, Nackaerts K, Gosselin R, et al. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma[J]. J Thorac Oncol, 2011, 6(11): 1930-1937.
|
| 13 |
Hooper CE, Lyburn ID, Searle J, et al. The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication[J]. Br J Cancer, 2015, 112(7): 1175-1182.
|
| 14 |
Takamori S, Toyokawa G, Shimokawa M, et al. The C-Reactive protein/albumin ratio is a novel significant prognostic factor in patients with malignant pleural mesothelioma: a retrospective multi-institutional study[J]. Ann Surg Oncol, 2018, 25(6): 1555-1563.
|
| 15 |
Gemba K, Fujimoto N, Aoe K, et al. Treatment and survival analyses of malignant mesothelioma in Japan[J]. Acta Oncol, 2013, 52(4): 803-808.
|
| 16 |
Tural Onur S, Sokucu SN, Dalar L, et al. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma[J]. Ther Clin Risk Manag, 2016, 12: 651-656.
|
| 17 |
Brims FJ, Meniawy TM, Duffus I, et al. A novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis[J]. J Thorac Oncol, 2016, 11(4): 573-582.
|
| 18 |
Rintoul RC, Ritchie AJ, Edwards JG, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial[J]. Lancet, 2014, 384(9948): 1118-1127.
|
| 19 |
Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs. chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial[J]. JAMA, 2012, 307(22): 2383-2389.
|
| 20 |
Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study[J]. Lancet Oncol, 2011, 12(8): 763-772.
|
| 21 |
Burkholder D, Hadi D, Kunnavakkam R, et al. Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma[J]. Ann Thorac Surg, 2015, 99(5): 1775-1180.
|
| 22 |
Cao C, Tian D, Park J, et al. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma[J]. Lung Cancer, 2014, 83(2): 240-245.
|
| 23 |
Lim E. 195 A feasibility study comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma: the MARS 2 study[J]. Lung Cancer, 2016, 91(1): S71.
|
| 24 |
van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase Ⅲ study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for research and treatment of cancer lung cancer group and the National Cancer Institute of Canada[J]. J Clin Oncol, 2005, 23(28): 6881-6889.
|
| 25 |
Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma[J]. J Clin Oncol, 2003, 21(14): 2636-2644.
|
| 26 |
Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2016, 387(10026): 1405-1414.
|
| 27 |
Jassem J, Ramlau R, Santoro A, et al. Phase Ⅲ trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma[J]. J Clin Oncol, 2008, 26(10): 1698-1704.
|
| 28 |
Krug LM, Kindler HL, Calvert H, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial[J]. Lancet Oncol, 2015, 16(4): 447-456.
|
| 29 |
Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial[J]. Lancet Oncol, 2017, 18(5): 623-630.
|
| 30 |
Fennell DA. Programmed Death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma[J]. J Thorac Oncol, 2018, 13(10): 1436-1437.
|
| 31 |
Clive AO, Taylor H, Dobson L, et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial[J]. Lancet Oncol, 2016, 17(8): 1094-1104.
|
| 32 |
Clive AO, Taylor H, Dobson L, et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial[J]. Lancet Oncol, 2016, 17(8): 1094-1104.
|